Clinical PhD Fellowships
Our clinical PhD fellowships are provided to develop and support future leaders in clinical cancer research.
About our clinical PhD fellowships
Our clinical PhD fellowships are provided to develop and support future leaders in clinical cancer research. The Clinical Academic Training Programme, ICR-Imperial is a programme which will provide clinical academics with the expertise to discover, develop, and deliver the next generation of treatments, technologies, and methodologies into clinical care.
The fellowships are typically three years in duration and will provide:
- a clinical salary;
- PhD registration fees at the UK rate;
- research running costs;
- Maximum Award amount is £287,288.
Applicants from a range of clinical specialities are invited to apply, including oncology, paediatrics, radiology, surgery, anaesthesia, and haematology.
Our academic clinicians form a vital link in our translational research, bringing knowledge of clinical practice into the laboratory and taking the knowledge of laboratory research back into the clinic and using it to help cancer patients.
Applications to our clinical PhD programme, commencing in autumn 2026, are now open.
To register your interest for future Clinical Research Fellowship opportunities, please email [email protected].
Our clinical PhD fellowships are funded through our ICR and Imperial Cancer Research UK Clinical Academic Training Partnership. These prestigious fellowships aim to support the training of future clinical academic leaders in cancer research.
Current opportunities
We are advertising a range of projects. You can read the project proposals below, and follow the links for more information. If the opportunities below don't interest you, you can sign up to our mailing list for future opportunities.
Find out how to apply See our entry requirements Sign up for our mailing list
"Targeted Biodegradable Nanogels for Intracellular Delivery of Therapeutic RNAs in Prostate Cancer"
Supervisory team: Dr Claire Fletcher, Dr Nazila Kamaly, Professor Charlotte Bevan
"Explainable Multi-Modal AI for Precision Checkpoint Inhibition Immunotherapy in Non-Small Cell Lung Cancer"
Supervisory team: Dr Mitchell Chen, Professor Eric Aboagye
"Investigating cytoskeletal dynamics in circulating tumour cells from breast cancer patients"
"Elucidating Relationships Between The Gut Microbiome And Lethal Prostate Cancer (PCa) Biology"
Supervisory team: Professor Johann de Bono, Professor Julian Marchesi and Dr Jia Li
"TEMPO-ER — Temporal & Spatial Regulation of ER in Health and Disease"
Supervisory Team: Professor Luca Magnani and Professor Nick Turner
"Improving CAR-T Cell Therapy Using Radiotherapy And Oncolytic Viruses"
Supervisory team: Professor Alan Melcher, Dr Emma Nicholson, Dr Ernesto Lopez
"SOMA-AI: Specimen intra-Operative Margin Assessment using Artificial Intelligence"
Supervisory team: Professor Ben Glocker, Ms Jennifer Rusby, Dr Richard Sidebottom, Ms Rachel O'Connell
"Deciphering the Evolution of Bispecific Antibody Resistance in Multiple Myeloma"
Supervisory team: Professor Richard Houlston and Professor Martin Kaiser-breast-cancer-cells-(green)-invading-through-a-layer-of-fibroblasts-(red)-(luke-henry-the-icr-2009).tmb-ctadt.jpg?Culture=en&sfvrsn=99d389e0_2)
"Modelling spatial features, interactions and transcriptional profiles at single-cell resolution that associate with CDK4/6 inhibitor treatment resistance in breast cancer"
Supervisory team: Professor Nick Turner, Professor Vahid Shahrezaei, Dr Eugene Schuster
"Studying the role of colorectal cancer associated fibroblasts (CAFs) on resistance to KRAS G12D inhibitors using multi-scale CRISPR screening co-culture systems and 3D vascularized microfluidic organoid models"
Supervisory team: Professor Udai Banerji, Dr Sam Au
"Platform trial to improve the Management of immUne reLated advErse evenTs (AMULET Study)"
Supervisory team: Dr Kate Young, Dr Duncan Gilbert, Prof Samra Turajlic, Prof James Larkin
"Longitudinal analyses in patients with inherited genetic susceptibility: real-world data science meets early detection/prevention of cancer"
Supervisory team: Professor Clare Turnbull, Professor Amanda Cross
"Smart Biopsy for Precision Therapeutics in Prostate Cancer: MRI/CBCT Fusion and Robotic Guidance to Improve Molecular Adequacy of Bone Metastasis Biopsies"
Supervisory team: Dr Edward Johnston, Dr Matt Blackledge, Professor Ferdinando Rodriguez y Baena, Professor Johann De Bono
"Understanding microenvironmental responses to radiation in gastrointestinal cancers"
Supervisory team: Magnus Dillon, Kevin Harrington, Anguraj Sadanandam, Alan Melcher, Arabella Hunt (RMH)
"Integrating Artificial Intelligence and Virtual Pathology to Transform Drug Response Prediction in Oesophageal Cancer"
Supervisory team: Dr Sung Pil Hong, Professor Robert Goldin, Dr Monica Terlizzo, Dr Wenjia Bai
"Investigating the immunomodulatory effect of intervention therapy for T-cell leukaemia in the premalignant stage"
Supervisory team: Dr Aileen Rowan (ICL), Dr Lucy Cook (ICNHT/ICL), Dr Maggie Cheang (ICR)).jpg?sfvrsn=83bdab30_1)
"Uncovering Clinical Drug Sequencing Patterns Using AI and Longitudinal EHR Data"
Supervisory team: Professor Dennis Wang, Professor Paul Huang
"Development of ECM-targeting CAR-T Cell Therapy"
Supervisory team: Professor Paul Huang, Dr Astero Klampatsa, Professor Terry Rabbitts, Professor Robin Jones-being-attacked-by-two-cytotoxic-t-cells-(red)-547x410.tmb-ctadt.png?Culture=en&sfvrsn=8f59440b_2)
"Developing anti-cancer immunotherapy in high-grade neuroendocrine carcinoma (HG-NEC): the PELICAN phase II study"
Supervisory team: Professor David James Pinato, Professor Julian Marchesi